(2006040828)

15.06.06

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 July 2005 (14.07.2005)

PCT

(10) International Publication Number
WO 2005/063226 A1

(51) International Patent Classification[7]: A61K 31/16, 31/155, 31/13

(21) International Application Number:
PCT/US2004/042884

(22) International Filing Date:
20 December 2004 (20.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/531,119 19 December 2003 (19.12.2003) US
60/591,709 27 July 2004 (27.07.2004) US

(71) Applicant *(for all designated States except US)*: **OMEGA BIO-PHARMA (I.P.3) LIMITED** [—/CN]; Unit 714, 7/F, Miramar Tower, 1-23 Kimberley Road, Tsim Sha Tsui, Kowloon, Hong kong (CN).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CHAN, Bill, Piu** [US/CN]; #6-2-8A, Citichamp Palace, Madian,, Haidan District, Beijing, 100088 (CN). **WONG, Gary, Kwan, Po** [—/CN]; Rm 1032 Nam Wai House, Nam Shan Estate, Kowloon (CN). **XU, Jinxian** [CN/CN]; T33-603, N°916 Bo Xing Road, Pudong, Shanghai (CN). **CHI, Francis** [PG/CN]; Flat D, 11/F, Tower 10, Beverly Villas, 16 La Salle Road, Kowloon, Hong Kong (CN).

(74) Agents: **EFRON, Margaret** et al.; Saliwanchik, Lloyd & Saliwanchik, PO Box 142950, A Professional Association, Gainesville, FL 32614-2950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



162162



ACTION

WO 2005/063226 A1

(54) Title: COMPOSITIONS AND METHODS FOR TREATING DIABETES

(57) Abstract: The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and/or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and/or treat diabetes as well as prevent and/or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity.